Related Experiment Video

Updated: May 13, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic

Alessandra Fabi1, Roberta Merola, Gianluigi Ferretti

  • 1Regina Elena National Cancer Institute, Department of Oncology A, Via Elio Chianesi, 53, 00144 Rome, Italy. fabi@ifo.it

Expert Opinion on Pharmacotherapy
|March 12, 2013
PubMed
Abstract

Insights

Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) greater than 3.36 predicts response to lapatinib in HER2-positive metastatic breast cancer patients. This finding may help identify patients who will benefit most from this dual tyrosine kinase inhibitor therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Lapatinib combined with capecitabine is a standard treatment for HER2-positive metastatic breast cancer (BC) progressing after trastuzumab therapy.
  • Drug resistance frequently limits the efficacy of lapatinib-based treatments.
  • Identifying biomarkers predictive of response is crucial for optimizing patient selection.

Purpose of the Study:

  • To evaluate the Epidermal Growth Factor Receptor (EGFR) protein and gene status as potential biomarkers for predicting response to lapatinib in metastatic HER2-positive BC.
  • To analyze the correlation between EGFR gene copy number (GCN) and patient response to lapatinib treatment.

Main Methods:

  • Fifty metastatic HER2-positive BC patients were analyzed.
  • EGFR protein expression was assessed by immunohistochemistry.
  • EGFR gene copy number (GCN) was determined by Fluorescence In Situ Hybridization (FISH).
  • Receiver operating curve (ROC) analysis was used to establish a cut-off value for EGFR GCN.

Main Results:

  • A statistically significant correlation was found between an EGFR GCN value greater than 3.36 copies/nucleus and response to lapatinib (p = 0.01).
  • Cox regression analysis identified HER2 score 3+ and increased EGFR GCN as positive predictors of response.
  • The cut-off value of > 3.36 EGFR copies/nucleus effectively discriminated responders from non-responders.

Conclusions:

  • Elevated EGFR GCN may serve as a predictive biomarker for identifying patients with HER2-positive metastatic breast cancer who are particularly responsive to the dual tyrosine kinase inhibitor, lapatinib.
  • Further research is warranted to validate these findings in larger patient cohorts.
  • EGFR GCN could be a valuable tool for patient screening to personalize lapatinib therapy.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...